# Protocol Synopsis: BV-CAR20-P1

**Protocol Title**: A Phase 1/2a Open-label, Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects with r/r NHL or r/r CLL/SLL.

## 1. Study Design
- **Phase**: 1 (Dose Escalation).
- **Strategy**: Standard **3+3 Dose Escalation**.
- **Indication**: Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL).
- **Therapy**: PBCAR20A (Anti-CD20 CAR-T), preceded by Lymphodepletion (Fludarabine/Cyclophosphamide).

## 2. Dose Levels
| Cohort | Dose Level (Cells) | Calculation |
|:---|:---|:---|
| **DL1** | 30 x 10^6 | Flat Dose |
| **DL2** | 240 x 10^6 | Flat Dose (Skipped per Amendment) |
| **DL3** | 480 x 10^6 | Flat Dose |

## 3. Analysis Populations
- **Safety**: All subjects receiving any study treatment (incl. Lymphodepletion).
- **ITT**: All enrolled subjects.
- **DLT Evaluable**: Subjects receiving PBCAR20A who complete 28-day window or experience DLT.

## 4. Key Endpoints
- **Primary**: Safety & MTD (Frequency of DLTs).
- **Secondary**: Objective Response Rate (ORR), Duration of Response (DoR).
- **AESIs**: CRS, ICANS, GvHD.

---
*Note: This synopsis reflects the Protocol as amended to discontinue Phase 2a expansion.*
